NEWS

Serbia

Serbia

The Serbian pharmaceutical market is being constrained by a focus on cost-containment and drug prices by the RFZO with a drive towards fiscal consolidation by the Serbian government. The worsening macroeconomic outlook for the Serbian economy in 2015 and 2016 will have a tangible effect on households, and this will, in turn, impact pharmaceutical sales given the large out-of-pocket expenditures by consumers on healthcare.
This market is characterized by modest size, decent growth rates, and heavy domination of generics as compared to other Eastern European countries. Pharmaceutical market is estimated by BMI at € 754mn in 2015 and Healthcare €3.41.4bn in 2015.